SCHEMBL1992827

SCHEMBL1992827

CS(=O)(=O)c1nc2c(c(CC(N)=O)n1)CCC2

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
POLB P06746 2/20 0.36
CYP1A2 P05177 2/20 0.36
GAA P10253 1/20 0.36
ALDH1A1 P00352 3/20 0.36
PDE4B Q07343 3/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 3/20 0.35
MAPT P10636 1/20 0.35
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
USP2 O75604 1/20 0.33
ADRB2 P07550 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1990556 0.97 SMN1; SMN2 (0.50) L3MBTL1SMN1; SMN2POLBCYP1A2GAA
SCHEMBL1070289 0.73 SMN1; SMN2 (0.55) L3MBTL1SMN1; SMN2POLBCYP1A2GAA
SCHEMBL1992191 0.72 SMN1; SMN2 (0.57) L3MBTL1SMN1; SMN2POLBCYP1A2GAA
SCHEMBL1997843 0.70 HTR2C (0.41) SMN1; SMN2CYP1A2GAAALDH1A1KDM4E
SCHEMBL1067810 0.70 SMN1; SMN2 (0.55) L3MBTL1SMN1; SMN2POLBCYP1A2GAA
SCHEMBL11277506 0.70 SMN1; SMN2 (0.59) L3MBTL1SMN1; SMN2POLBCYP1A2GAA
SCHEMBL1068543 0.69 SMN1; SMN2 (0.54) L3MBTL1SMN1; SMN2POLBCYP1A2ALDH1A1
SCHEMBL1991256 0.68 SMN1; SMN2 (0.61) L3MBTL1SMN1; SMN2POLBCYP1A2GAA
SCHEMBL1996163 0.68 HTR2C (0.41) SMN1; SMN2ALDH1A1KDM4E
SCHEMBL21963178 0.63 ACHE (0.45) L3MBTL1POLBCYP1A2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO L3MBTL1 3898/4885SMN1; SMN2 2548/4885POLB 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.